inWhite tw_white-black
MoreMenu
CloseWhite
inWhite tw_white-black

News

Asgard Therapeutics strengthens its Board of Directors and Advisory Board with leading experts in drug development and cancer immunotherapy

Asgard Therapeutics appoints immunology expert Shane Olwill as Chief Development Officer

Asgard Therapeutics’ study published in Science showing proof-of-concept and strong anti-tumor responses via in vivo cell reprogramming with lead program AT-108

Asgard Therapeutics selects Exothera to bring their viral vector-based immunotherapy candidate AT-108 to clinical trial stage

Asgard Therapeutic’s scientific founders publish the pioneering paper describing dendritic cell direct reprogramming in mouse cells.

Posted 25 December, 2018